Toxicity and treatment outcomes in dose escalated radiotherapy for upper third oesophageal carcinoma
May Myat Noe Win,
United Kingdom
PO-1289
Abstract
Toxicity and treatment outcomes in dose escalated radiotherapy for upper third oesophageal carcinoma
Authors: May Myat Noe Win1, Claire Barker2, Lubna Bhatt1, Hamid Sheikh3, Ganesh Radhakrishna1
1The Christie Hospital NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom; 2The Christie Hospital NHS Foundation Trust, Clinical Oncology, Manchester , United Kingdom; 3The Christie Hospital NHS Foundation Trust , Clinical Oncology, Manchester, United Kingdom
Show Affiliations
Hide Affiliations
Purpose or Objective
The incidence of the carcinoma of the upper third oesophagus is rare, accounting for 11% of all oesophageal cancer cases in the UK. Definitive chemo-radiotherapy (dCRT) is the recommended treatment option in patients with the carcinoma of the upper third oesophagus. This “real-world” data aimed to provide the treatment outcomes and toxicity for patients treated with dose-escalated radiotherapy (RT) for upper third oesophageal cancer.
Material and Methods
This was a retrospective study of patients treated at the Christie Hospital between 2010 and 2021. 44 patients (male=24, female =20) were identified with squamous cell carcinoma of the upper third oesophagus. RT was delivered using either IG -IMRT or VMAT with 60-67 Gy in 30 fractions with daily volumetric imaging. 40 Patients received concurrent chemotherapy including 31 patients who were also given induction chemotherapy. The regimes were platinum based, with 2 patients receiving cetuximab.
Results
Median age at treatment was 63 (range 27-79).
All patients completed 30 fractions of RT. Grade 3 toxicities (CTCAE version 5) were
observed in 12 patients (27%): oesophagitis in 7 patients (16%) with 3 patients
requiring emergency gastrostomy insertion, nausea and vomiting in 3 patients
(7%) and non-neutropenic sepsis in 2 patients (4%). The 30-day mortality and
90-day mortality rates were 2% and 7% respectively. 50% of patients at 6
month follow-up had subjective improvement in dysphagia.
At a median follow-up of 19 months
(0-83months), 6 patients (14%) developed local relapse
in the high dose radiotherapy field and 14 patients (32%) developed distant
metastases. Median overall survival
(OS) was 23 months. OS at 1 and 2 year
were 78% and 48% respectively. Median progression-free survival (PFS) was 15
months and PFS at 1 year and 2 year were 53% and 38% respectively. Data will be
matured at the time of presentation.
Conclusion
This study demonstrates that dose-escalated RT of 60-67Gy has an acceptable safety profile and offers improved local disease control in patients with upper third oesophageal cancer. Further studies on dose escalated RT in upper third oesophageal cancer are required.